6th European Congress of Immunology

6th European Congress of Immunology

September 1–4, 2021

ECI 2021– A success for moving immunology research forward 

Amongst other big research topics in immunology, the meeting spotlighted the latest developments regarding COVID-19, which we also addressed in our symposium, “Latest findings and innovative solutions in SARS-CoV-2 research”. Many joined us at ECI 2021, visited our booth, participated in our symposium, and learned more about our latest solutions for their SARS-CoV-2 and further immunology research. 

If you missed us or would like to see the talk again, watch the recording below.

Recorded talk

Latest findings and innovative solutions in SARS-CoV-2 research

Since the emergence of the COVID-19 pandemic, extensive studies have explored disease pathogenesis, as well as acquired and induced immunity against the infection. With the recent development and dissemination of COVID-19 vaccinations, cellular analysis of  T and B cells has become crucial not only for patient monitoring, but also in evaluating the efficiency of immunization of candidate and established vaccines.  
As presented in the introduction by Dr. Marcello Stein, working with these rare cells can prove challenging to researchers. Therefore, Miltenyi Biotec offers a complete workflow for isolation, stimulation, sorting, and analysis of virus-specific immune cells.  
 The innovative product solutions hereby address key challenges such as low cell frequencies, unspecific labeling, and high background staining. 
A study with over 900 individuals from the SARS-CoV-2 hotspot in Heinsberg, Germany, in collaboration with Miltenyi Biotec and the methods therein is outlined by Dr. Ryan G. Nattrass, including results from humoral and cellular responses in relation to the course of disease.  
In addition to that, Dr. Laura Maggi will talk about the characterization of the adaptive immune response to SARS-CoV-2, including both the humoral and cell-mediated arm in response to mRNA vaccination in different cohorts of subjects.


Dr. Ryan G. Nattrass

University Hospital Bonn, Germany

Ryan G. Nattrass earned his Ph.D. at the University of Liverpool successfully developing a mouse model of antibiotic-induced immune-mediated liver damage. Thereafter, he started his first position in 2018 at the University of Essen at the Institute of HIV. His works concentrated on a collaborative project looking at the effect of de-glycosylation on the effectiveness of a potential HIV-vaccine in a murine model, and the effects of long-term HIV-treatment on the human immune system. He is currently based at the University Hospital Bonn at the Institute of Virology working under Prof. Dr. Streeck on the SARS-CoV-2 virus and its effects on the immune system in those with mild/moderate COVID-19 symptoms.

Dr. Laura Maggi

University of Florence, Italy

Laura Maggi obtained her Ph.D. at University of Florence studying the modulation of CD4+ T cell phenotype in response to CXCR3 stimulation. Since 2017, she is assistant professor in General Pathology at the University of Florence, Dept. of Experimental and Clinical Medicine. Her research activity was mainly dedicated to investigating the role of different subsets of adaptive T helper cells in the pathogenesis of many human diseases (atopy, immunodeficiency, autoimmunity disorders, and cancer) and to define the effect of biological drugs on the immune response. In the last years, she extended her investigation also to innate lymphoid cells (ILC) subsets and just one years ago, she has been involved in the featuring of the adaptive immune response against SARS-CoV-2 in both natural infection and after vaccination. 

Dr. Marcello Stein

Miltenyi Biotec

Dr. Stein received his doctoral degree in immunology and genetics from the University of Erlangen-Nuremberg, Germany, in 2011. After two years of post-doctoral studies at the Department of Immune Modulation at the University Hospital Erlangen and three years as Product Manager Life Science at Peqlab Biotec and VWR International, Dr. Stein joined Miltenyi Biotec as Global Product Manager and Group Leader Immunology T cells in the Marketing Department. His team focuses primarily on the translational research T cell product portfolio and covers amongst others workflows for CAR T cell research, antigen-specific T cells, regulatory T cells, and COVID-19.

Related information